RWD298 PUBLIC HEALTH IMPACT ASSESSMENT OF RSVPREF3 OA ADJUVANTED VACCINE ON RESPIRATORY SYNCYTIA VIRUS IN TAIWAN, HONG KONG, AND SINGAPORE
Respiratory syncytial virus (RSV) is a contagious pathogen that causes acute respiratory illness (ARI) in individuals of all ages and represents a significant health burden among older adults (OAs) aged ≥60 years in Asia. In this population, RSV can lead to lower respiratory tract disease (LRTD) and complications such as pneumonia, exacerbations of chronic respiratory disease, cardiovascular complications, ICU admissions, and death.This study aims to evaluate the potential public health impact (PHI) of the GSK RSVPreF3 OA adjuvanted vaccine, the first approved preventive intervention for RSV for OAs aged ≥60 in Hong Kong, Singapore, and Taiwan.
Authors
- Chit Laa Poh (ORCID: https://orcid.org/0000-0001-8475-6291)
- Han Na Lee (ORCID: https://orcid.org/0000-0001-6084-262X)
- Yu-Fan Ho (ORCID: https://orcid.org/0000-0003-1943-5533)
- Kam‐Lun Ellis Hon (ORCID: https://orcid.org/0000-0002-6682-5529)
- Yhu‐Chering Huang (ORCID: https://orcid.org/0000-0003-4351-8953)
- Pin-Kuei Fu (ORCID: https://orcid.org/0009-0009-1843-4513)
- Ivan Fan-Ngai Hung (ORCID: https://orcid.org/0000-0003-3323-958X)
- Limin Wijaya
- Helen May Lin Oh
- M K Ko
- Aruni K. Seneviratna
- Beverly Giam
Institutions
- SingHealth (SG)
- Chinese University of Hong Kong (HK)
- GlaxoSmithKline (United Kingdom) (GB)
- Chang Gung Memorial Hospital (TW)
- Taichung Veterans General Hospital (TW)
- Prince of Wales Hospital (CN)
- GlaxoSmithKline (China) (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Value in Health Regional Issues
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.vhri.2025.101447
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00